

# Kebede Begna

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8488548/kebede-begna-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130  
papers

1,302  
citations

17  
h-index

34  
g-index

139  
ext. papers

1,779  
ext. citations

4.8  
avg, IF

4.19  
L-index

#	Paper	IF	Citations
130	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 908-19	59.2	219
129	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , <b>2018</b> , 32, 1631-1642	10.7	117
128	A phase-2 trial of low-dose pomalidomide in myelofibrosis. <i>Leukemia</i> , <b>2011</b> , 25, 301-4	10.7	97
127	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , <b>2018</b> , 32, 1200-1210	10.7	68
126	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. <i>Leukemia</i> , <b>2018</b> , 32, 1189-1199	10.7	65
125	Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 155-166	6.4	55
124	Long-term outcome of pomalidomide therapy in myelofibrosis. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 66-8	7.1	55
123	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <i>Blood Advances</i> , <b>2018</b> , 2, 370-380	7.8	55
122	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 599-610	6.4	50
121	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , <b>2015</b> , 29, 741-4	10.7	33
120	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 12	7	28
119	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1511-1521	7.1	28
118	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 29	7	27
117	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e405	7	24
116	Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes. <i>International Journal of Cardiology</i> , <b>2019</b> , 275, 6-12	3.2	18
115	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 781-789	7.1	17
114	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. <i>Leukemia</i> , <b>2020</b> , 34, 656-661	10.7	17

113	BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. <i>Blood</i> , <b>2013</b> , 122, 664-664	2.2	15
112	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. <i>Blood Cancer Journal</i> , <b>2017</b> , 7, e550	7	14
111	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , <b>2015</b> , 29, 498-500	10.7	14
110	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 1363-1374	6.4	14
109	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 18	7	13
108	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , <b>2013</b> , 122, 394-394	2.2	13
107	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 866-871	7.1	12
106	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , <b>2018</b> , 71, 60-62	2.7	11
105	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 49	7	11
104	Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3160-3167	7.5	11
103	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 1623-38	6.4	10
102	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. <i>Blood Advances</i> , <b>2020</b> , 4, 5425-5430	7.8	10
101	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , <b>2011</b> , 118, 3849-3849	2.2	10
100	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. <i>Blood</i> , <b>2013</b> , 122, 662-662	2.2	10
99	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 1467-1474	6.4	8
98	Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e415	7	8
97	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 68	7	7
96	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 121	7	7

95	Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 2653-2659	6.5	7
94	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1592-1600	1.9	6
93	Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, e39-41	2	6
92	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <i>Modern Pathology</i> , <b>2020</b> , 33, 334-343	9.8	6
91	Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 1542-1550	15.0	5
90	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , <b>2017</b> , 130, 891-891	2.2	5
89	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 990-999	1.9	5
88	A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µCi/Kg/Dose. <i>Blood</i> , <b>2018</b> , 132, 1457-1457	2.2	4
87	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , <b>2016</b> , 128, 1123-1123	2.2	4
86	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. <i>Leukemia Research</i> , <b>2016</b> , 50, 112-115	2.7	4
85	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 764-767	1.9	4
84	Real-World Myelodysplastic Syndrome-unclassifiable and Its Comparison With Refractory Cytopenia With Multi-Lineage dysplasia and Refractory anemia. <i>Blood</i> , <b>2013</b> , 122, 1574-1574	2.2	3
83	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. <i>Blood</i> , <b>2015</b> , 126, 55-55	2.2	3
82	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , <b>2016</b> , 128, 2798-2798	2.2	3
81	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , <b>2016</b> , 128, 3604-3604	2.2	3
80	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	3
79	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA + venetoclax chemotherapy. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E108-E111	7.1	3
78	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. <i>Blood Advances</i> , <b>2021</b> , 5, 2272-2278	7.8	3

77	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 5-9	7.1	3
76	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E164-E166	7.1	2
75	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2483-2487	1.9	2
74	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E257	7.1	2
73	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	2
72	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. <i>Blood</i> , <b>2021</b> , 138, 219-219	2.2	2
71	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E68-E72	7.1	2
70	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2119-2124	3	2
69	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. <i>American Journal of Clinical Pathology</i> , <b>2021</b> , 156, 679-690	1.9	2
68	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. <i>Annals of Hematology</i> , <b>2019</b> , 98, 331-337	3	2
67	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , <b>2021</b> , 11, 1-9	2.6	2
66	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E401-E404	7.1	2
65	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	2
64	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> ,	4.5	2
63	Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1993-1994	3	1
62	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 244-248	4.5	1
61	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. <i>Annals of Hematology</i> , <b>2020</b> , 99, 513-518	3	1
60	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e1117-e1122	3.3	1

59	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E626-E627	7.1	1
58	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 7	7	1
57	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 26	7	1
56	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. <i>Haematologica</i> , <b>2022</b> ,	6.6	1
55	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , <b>2018</b> , 132, 3035-3035	2.2	1
54	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , <b>2013</b> , 122, 2821-2821	2.2	1
53	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , <b>2013</b> , 122, 4049-4049	2.2	1
52	Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. <i>Blood</i> , <b>2015</b> , 126, 4078-4078	2.2	1
51	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. <i>Blood</i> , <b>2016</b> , 128, 2451-2451	2.2	1
50	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , <b>2011</b> , 118, 1752-1752	2.2	1
49	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 1476-1476	2.2	1
48	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 46	7	1
47	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E398-E401	7.1	1
46	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , <b>2021</b> , 127, 4421-4431	6.4	1
45	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 413-416	4.5	1
44	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	1
43	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 55	7	1
42	Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 229-232	1.9	0

41	Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	0
40	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , <b>2011</b> , 118, 1759-1759	2.2	0
39	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , <b>2021</b> , 138, 3657-3657	2.2	0
38	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , <b>2021</b> , 138, 3368-3368	2.2	0
37	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. <i>Blood</i> , <b>2016</b> , 128, 5534-5534	2.2	0
36	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	0
35	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E144-E146	7.1	
34	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , <b>2020</b> , 136, 35-36	2.2	
33	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	
32	Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141). <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	
31	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 12	7	
30	A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML. <i>Blood</i> , <b>2021</b> , 138, 3423-3423	2.2	
29	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. <i>Blood</i> , <b>2021</b> , 138, 36-36	2.2	
28	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , <b>2021</b> , 138, 1267-1267	2.2	
27	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , <b>2021</b> , 138, 1096-1096	2.2	
26	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , <b>2021</b> , 138, 4656-4656	2.2	
25	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. <i>Blood</i> , <b>2021</b> , 138, 3377-3377	2.2	
24	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. <i>Blood</i> , <b>2017</b> , 130, 927-927	2.2	

23	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. <i>Blood</i> , <b>2018</b> , 132, 1443-1443	2.2
22	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. <i>Blood</i> , <b>2018</b> , 132, 5510-5510	2.2
21	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronically after the FDA Approval Date of Anagrelide. <i>Blood</i> , <b>2018</b> , 132, 4287-4287	2.2
20	Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study. <i>Blood</i> , <b>2018</b> , 132, 2658-2658	2.2
19	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. <i>Blood</i> , <b>2018</b> , 132, 3100-3100	2.2
18	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , <b>2018</b> , 132, 2689-2689	2.2
17	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , <b>2018</b> , 132, 3044-3044	2.2
16	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , <b>2019</b> , 134, 3005-3005	2.2
15	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , <b>2019</b> , 134, 5441-5441	2.2
14	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , <b>2019</b> , 134, 5406-5406	2.2
13	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , <b>2019</b> , 134, 3863-3863	2.2
12	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , <b>2015</b> , 126, 4062-4062	2.2
11	Molecular Correlates of Anemia in Primary Myelofibrosis. <i>Blood</i> , <b>2015</b> , 126, 4068-4068	2.2
10	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. <i>Blood</i> , <b>2015</b> , 126, 2875-2875	2.2
9	Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. <i>Blood</i> , <b>2016</b> , 128, 1617-1617	2.2
8	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. <i>Blood</i> , <b>2016</b> , 128, 1996-1996	2.2
7	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. <i>Blood</i> , <b>2011</b> , 118, 3795-3795	2.2
6	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. <i>Blood</i> , <b>2011</b> , 118, 3833-3833	2.2



- 5 Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 423-423
- 4 Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. *Blood*, **2013**, 122, 4048-4048 2.2
- 3 Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1334-1334 2.2
- 2 Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. *Blood*, **2013**, 122, 5000-5000 2.2
- 1 44-Year-Old Man With Fatigue, Weight Loss, and Leukocytosis. *Mayo Clinic Proceedings*, **2021**, 96, 1944-1948